title: Hypersensitivity pneumonitis related to imatinib mesylate.
authors.forename: A
authors.initials: A
authors.lastname: Bergeron
authors.forename: E
authors.initials: E
authors.lastname: Bergot
authors.forename: G
authors.initials: G
authors.lastname: Vilela
authors.forename: L
authors.initials: L
authors.lastname: Ades
authors.forename: A
authors.initials: A
authors.lastname: Devergie
authors.forename: H
authors.initials: H
authors.lastname: Espérou
authors.forename: G
authors.initials: G
authors.lastname: Socié
authors.forename: F
authors.initials: F
authors.lastname: Calvo
authors.forename: E
authors.initials: E
authors.lastname: Gluckman
authors.forename: P
authors.initials: P
authors.lastname: Ribaud
authors.forename: Ph
authors.initials: P
authors.lastname: Rousselot
authors.forename: A
authors.initials: A
authors.lastname: Tazi
mesh_terms: D000328:Adult; D000542:Alveolitis, Extrinsic Allergic / Q000139:chemically induced*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D010879:Piperazines / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate